"Immunol Med"[ Journal] - Search Results

Year	Number of Results
2018	31
2019	31
2020	44
2021	48
2022	37
2023	33
2024	22

1

New-onset of rheumatic diseases following COVID-19 vaccination: the report of three cases and a literature review.

Matsuda M, Funakubo Asanuma Y, Emoto K, Sakai S, Okumura N, Yazawa H, Maruyama T, Tsuzuki Wada T, Yokota K, Araki Y, Akiyama Y, Mimura T. Matsuda M, et al. Immunol Med. 2024 Apr 16:1-12. doi: 10.1080/25785826.2024.2339542. Online ahead of print. Immunol Med. 2024. PMID: 38627989

2

Fatal hemophagocytic lymphohistiocytosis with intravascular large B-cell lymphoma following coronavirus disease 2019 vaccination in a patient with systemic lupus erythematosus: an intertwined case.

Ueda Y, Sakai T, Yamada K, Arita K, Ishige Y, Hoshi D, Yanagisawa H, Iwao-Kawanami H, Kawanami T, Mizuta S, Fukushima T, Yamada S, Yachie A, Masaki Y. Ueda Y, et al. Immunol Med. 2024 Apr 15:1-8. doi: 10.1080/25785826.2024.2338594. Online ahead of print. Immunol Med. 2024. PMID: 38619098

3

Evolution of diagnostic criteria and new insights into clinical testing in mixed connective tissue disease; anti-survival motor neuron complex antibody as a novel marker of severity of the disease.

Kubo S, Tanaka Y. Kubo S, et al. Immunol Med. 2024 Apr 10:1-6. doi: 10.1080/25785826.2024.2338593. Online ahead of print. Immunol Med. 2024. PMID: 38597289 Review.

4

Successful high-dose glucocorticoid therapy for anti-mitochondrial antibody-positive myocarditis arising during tocilizumab and low-dose glucocorticoid therapy for rheumatoid arthritis.

Suzuki K, Akiyama M, Saito S, Kaneko Y. Suzuki K, et al. Immunol Med. 2024 Apr 5:1-5. doi: 10.1080/25785826.2024.2336689. Online ahead of print. Immunol Med. 2024. PMID: 38578159

5

Successful treatment with tofacitinib for anti-melanoma differentiation-associated gene 5 antibody-positive juvenile dermatomyositis: case reports and review of the literature.

Yamazaki S, Shimizu M, Yakabe A, Inage E, Jimbo K, Suzuki M, Miyaoka F, Kaneko S, Irabu H, Shimbo A, Ohtomo Y, Mori M, Morio T, Shimizu T. Yamazaki S, et al. Immunol Med. 2024 Apr 1:1-8. doi: 10.1080/25785826.2024.2336687. Online ahead of print. Immunol Med. 2024. PMID: 38557269

6

Establishment of novel cell lines that maintain the features of B cells derived from patients with neuromyelitis optica spectrum disorder.

Sano S, Yoshikawa S, Hoshino Y, Tomizawa Y, Hattori N, Miyake S. Sano S, et al. Immunol Med. 2024 Mar 27:1-9. doi: 10.1080/25785826.2024.2334002. Online ahead of print. Immunol Med. 2024. PMID: 38539091

7

High frequency of circulating non-classical monocytes is associated with stable remission in relapsing-remitting multiple sclerosis.

Minote M, Sato W, Kimura K, Kimura A, Lin Y, Okamoto T, Takahashi R, Yamamura T. Minote M, et al. Immunol Med. 2024 Mar 27:1-15. doi: 10.1080/25785826.2024.2331271. Online ahead of print. Immunol Med. 2024. PMID: 38539051

8

Anti-aminoacyl tRNA synthetase antibodies showing the discrepancy between enzyme-linked immunosorbent assay and RNA-immunoprecipitation.

Sasai T, Ishikawa Y, Nakashima R, Isayama T, Tanizawa K, Handa T, Shirakashi M, Hiwa R, Tsuji H, Kitagori K, Akizuki S, Yoshifuji H, Mimori T, Morinobu A. Sasai T, et al. Immunol Med. 2024 Mar 15:1-10. doi: 10.1080/25785826.2024.2328918. Online ahead of print. Immunol Med. 2024. PMID: 38488763

9

Involvement of YKL-40-positive macrophages commonly identified in polymyositis and dermatomyositis in the pathogenesis of myositis: a retrospective study.

Noguchi K, Furukawa T, Tatsumi Y, Kasama S, Yoshikawa T, Hashimoto T, Azuma N, Hirota S, Kimura T, Matsui K. Noguchi K, et al. Immunol Med. 2024 Mar;47(1):37-44. doi: 10.1080/25785826.2023.2264007. Epub 2023 Oct 10. Immunol Med. 2024. PMID: 37817562

10

Predictive value of baseline concomitant glucocorticoid for abatacept-mediated long-term inhibition of radiographic progression: insights from the KURAMA cohort.

Murakami K, Watanabe R, Fujisaki T, Ito H, Murata K, Yamamoto W, Fujii T, Onizawa H, Onishi A, Tanaka M, Hashimoto M, Morinobu A. Murakami K, et al. Immunol Med. 2024 Mar;47(1):45-51. doi: 10.1080/25785826.2023.2265148. Epub 2023 Oct 3. Immunol Med. 2024. PMID: 37789658

11

A new therapeutic target for systemic lupus erythematosus: the current landscape for drug development of a toll-like receptor 7/8 antagonist through academia-industry-government collaboration.

Tanaka Y, Tago F, Yamakawa N, Aoki M, Yagi T, Akira S. Tanaka Y, et al. Immunol Med. 2024 Mar;47(1):24-29. doi: 10.1080/25785826.2023.2264023. Epub 2023 Sep 29. Immunol Med. 2024. PMID: 37772762 Review.

12

Pathophysiology and stratification of treatment-resistant rheumatoid arthritis.

Yamada S, Nagafuchi Y, Fujio K. Yamada S, et al. Immunol Med. 2024 Mar;47(1):12-23. doi: 10.1080/25785826.2023.2235734. Epub 2023 Jul 18. Immunol Med. 2024. PMID: 37462450 Review.

13

Comparison and effect of plain and calcium fortified yogurt on glycemic responses, anthropometrics and metabolic biomarkers.

Draz A, Jaffar HM, Rizwan B, Sukhera S, Batool SA, Noreen S, Koser N, Islam Z. Draz A, et al. Immunol Med. 2024 Mar;47(1):30-36. doi: 10.1080/25785826.2023.2228074. Epub 2023 Jun 30. Immunol Med. 2024. PMID: 37387250

14

Osteoclast differentiation in rheumatoid arthritis.

Yokota K. Yokota K. Immunol Med. 2024 Mar;47(1):6-11. doi: 10.1080/25785826.2023.2220931. Epub 2023 Jun 13. Immunol Med. 2024. PMID: 37309864 Review.

15

Immunotherapy in small bowel adenocarcinoma: a potential role?

Vitiello F, Cereda S, Foti S, Liscia N, Mazza E, Ronzoni M, Cascinu S. Vitiello F, et al. Immunol Med. 2024 Mar;47(1):1-5. doi: 10.1080/25785826.2023.2220938. Epub 2023 Jun 9. Immunol Med. 2024. PMID: 37293784 Review.

16

Safety risks of interstitial lung disease upon real-world usage of Janus kinase inhibitors and biologics for patients with autoimmune diseases: epidemiological study using nationwide electronic medical record database in Japan.

Yabuuchi M, Yokoyama K. Yabuuchi M, et al. Immunol Med. 2024 Feb 21:1-12. doi: 10.1080/25785826.2024.2311763. Online ahead of print. Immunol Med. 2024. PMID: 38379433

17

Prophylactic immunoglobulin therapy for pediatric congenital myotonic dystrophy.

Uejima Y, Sato S. Uejima Y, et al. Immunol Med. 2024 Jan 25:1-4. doi: 10.1080/25785826.2024.2306672. Online ahead of print. Immunol Med. 2024. PMID: 38270551

18

NF9 peptide specific cytotoxic T lymphocyte clone cross react to Y453F mutation of SARS-CoV-2 virus spike protein.

Murai A, Kubo T, Ohkuri T, Yanagawa J, Yajima Y, Kosaka A, Li D, Nagato T, Murata K, Kanaseki T, Tsukahara T, Nagasaki T, Hirohashi Y, Kobayashi H, Torigoe T. Murai A, et al. Immunol Med. 2024 Jan 18:1-7. doi: 10.1080/25785826.2024.2304363. Online ahead of print. Immunol Med. 2024. PMID: 38236134

19

Efficacy and safety of mycophenolate mofetil for steroid reduction in neuromyelitis optica spectrum disorder: a prospective cohort study.

Akatani R, Chihara N, Koto S, Mori S, Kurimoto T, Nakamura M, Tachibana H, Otsuka Y, Ueda T, Omori T, Sekiguchi K, Matsumoto R. Akatani R, et al. Immunol Med. 2024 Jan 18:1-8. doi: 10.1080/25785826.2024.2304364. Online ahead of print. Immunol Med. 2024. PMID: 38235761

20

Risk of disease flares after SARS-CoV-2 mRNA vaccination in patients with systemic lupus erythematosus.

Kikuchi J, Kondo Y, Kojima S, Kasai S, Sakai Y, Takeshita M, Hiramoto K, Saito S, Fukui H, Hanaoka H, Suzuki K, Kaneko Y. Kikuchi J, et al. Immunol Med. 2024 Jan 8:1-9. doi: 10.1080/25785826.2023.2300163. Online ahead of print. Immunol Med. 2024. PMID: 38189429

21

Possible correlation between serum interleukin-8 levels and the activity of myositis in anti-NXP2 antibody-positive dermatomyositis.

Konishi R, Ichimura Y, Tanaka R, Miyahara H, Okune M, Miyamoto M, Hara M, Iwabuchi A, Takada H, Nakagishi Y, Mizuta M, Kaneko S, Shimizu M, Morio T, Nishino I, Nomura T, Okiyama N. Konishi R, et al. Immunol Med. 2024 Jan 4:1-6. doi: 10.1080/25785826.2023.2300553. Online ahead of print. Immunol Med. 2024. PMID: 38174692

22

Synovial-tissue resident macrophages play proinflammatory functions in the pathogenesis of RA while maintaining the phenotypes in the steady state.

Kai K, Yamada H, Tsurui R, Sakuraba K, Fujimura K, Kawahara S, Akasaki Y, Tsushima H, Fujiwara T, Hara D, Fukushi JI, Sawa S, Nakashima Y. Kai K, et al. Immunol Med. 2024 Jan 3:1-10. doi: 10.1080/25785826.2023.2300853. Online ahead of print. Immunol Med. 2024. PMID: 38168669

23

C5a stimulation induces caspase-1 activation and mature IL-1β production in human peripheral blood mononuclear cells.

Fujita Y, Matsumoto H, Inada K, Onizawa M, Saito K, Sumichika Y, Yoshida S, Temmoku J, Matsuoka N, Asano T, Sato S, Machida T, Migita K. Fujita Y, et al. Immunol Med. 2023 Dec 15:1-8. doi: 10.1080/25785826.2023.2292665. Online ahead of print. Immunol Med. 2023. PMID: 38099557

24

Involvement of the complement system in immune thrombocytopenia: review of the literature.

Shindo R, Abe R, Oku K, Tanaka T, Matsueda Y, Wada T, Arinuma Y, Tanaka S, Ikenoue T, Miyakawa Y, Yamaoka K. Shindo R, et al. Immunol Med. 2023 Dec;46(4):182-190. doi: 10.1080/25785826.2023.2213976. Epub 2023 May 26. Immunol Med. 2023. PMID: 37237432 Review.

25

Macrophage activation syndrome triggered by methotrexate-related lymphoproliferative disease in a patient with rheumatoid arthritis.

Kato H, Suzuki M, Misumi K, Kohsaka H. Kato H, et al. Immunol Med. 2023 Dec;46(4):191-195. doi: 10.1080/25785826.2023.2212808. Epub 2023 May 18. Immunol Med. 2023. PMID: 37199221

26

Clinical practice guideline for activated phosphatidyl inositol 3-kinase-delta syndrome in Japan.

Moriya K, Mitsui-Sekinaka K, Sekinaka Y, Endo A, Kanegane H, Morio T, Imai K, Nonoyama S. Moriya K, et al. Immunol Med. 2023 Dec;46(4):153-157. doi: 10.1080/25785826.2023.2210366. Epub 2023 May 13. Immunol Med. 2023. PMID: 37178059 Review.

27

The effects of grapes and their products on immune system: a review.

Izadfar F, Belyani S, Pormohammadi M, Alizadeh S, Hashempor M, Emadi E, Sangsefidi ZS, Jalilvand MR, Abdollahi S, Toupchian O. Izadfar F, et al. Immunol Med. 2023 Dec;46(4):158-162. doi: 10.1080/25785826.2023.2207896. Epub 2023 May 9. Immunol Med. 2023. PMID: 37158605 Review.

28

An in silico approach for prediction of B cell and T cell epitope candidates against Chikungunya virus.

Venkatesan A, Chouhan U, Suryawanshi SK, Choudhari JK. Venkatesan A, et al. Immunol Med. 2023 Dec;46(4):163-174. doi: 10.1080/25785826.2023.2202038. Epub 2023 Apr 20. Immunol Med. 2023. PMID: 37078425

29

Association of IL-17 serum levels with clinical findings and systemic lupus erythematosus disease activity index.

Ebrahimi Chaharom F, Ebrahimi AA, Feghhi Koochebagh F, Babalou Z, Ghojazadeh M, Aghebati Maleki L, Nader ND. Ebrahimi Chaharom F, et al. Immunol Med. 2023 Dec;46(4):175-181. doi: 10.1080/25785826.2023.2202050. Epub 2023 Apr 19. Immunol Med. 2023. PMID: 37073815

30

Exploring the role of Janus kinase (JAK) in atopic dermatitis: a review of molecular mechanisms and therapeutic strategies.

Kogame T, Egawa G, Kabashima K. Kogame T, et al. Immunol Med. 2023 Sep;46(3):112-120. doi: 10.1080/25785826.2023.2214324. Epub 2023 May 31. Immunol Med. 2023. PMID: 37254967 Free article. Review.

31

Understanding the efficacy of individual Janus kinase inhibitors in the treatment of ulcerative colitis for future positioning in inflammatory bowel disease treatment.

Nakase H. Nakase H. Immunol Med. 2023 Sep;46(3):121-130. doi: 10.1080/25785826.2023.2195522. Epub 2023 Apr 10. Immunol Med. 2023. PMID: 37036140 Review.

32

JAK inhibitors ∼ overview∼.

Kameda H. Kameda H. Immunol Med. 2023 Sep;46(3):108-111. doi: 10.1080/25785826.2023.2183594. Epub 2023 Feb 27. Immunol Med. 2023. PMID: 36850046 Review.

33

JAK inhibitors in rheumatology.

Yamaoka K, Oku K. Yamaoka K, et al. Immunol Med. 2023 Sep;46(3):143-152. doi: 10.1080/25785826.2023.2172808. Epub 2023 Feb 6. Immunol Med. 2023. PMID: 36744577 Review.

34

Recent progress of JAK inhibitors for hematological disorders.

Kirito K. Kirito K. Immunol Med. 2023 Sep;46(3):131-142. doi: 10.1080/25785826.2022.2139317. Epub 2022 Oct 28. Immunol Med. 2023. PMID: 36305377 Review.

35

Hypocomplementemic urticarial vasculitis case with hemophagocytic lymphohistiocytosis following SARS-CoV-2 mRNA vaccination.

Iwamura N, Eguchi K, Koga T, Tsutsumi K, Araki T, Aramaki T, Takatani A, Terada K, Ueki Y. Iwamura N, et al. Immunol Med. 2023 Jun;46(2):97-107. doi: 10.1080/25785826.2023.2193286. Epub 2023 Mar 23. Immunol Med. 2023. PMID: 36950829

36

Metastatic pulmonary pleomorphic carcinoma replaced by a granulomatous lesion after spontaneous regression and PD-1 blockade-induced regression: can epithelioid granuloma be a histological hallmark of cancer immunity?

Shijubou N, Asai Y, Hosaka M, Segawa K, Kubo T, Miyajima M, Tsukahara T, Hirohashi Y, Kanaseki T, Murata K, Watanabe A, Hasegawa T, Chiba H, Torigoe T. Shijubou N, et al. Immunol Med. 2023 Jun;46(2):93-96. doi: 10.1080/25785826.2023.2193283. Epub 2023 Mar 22. Immunol Med. 2023. PMID: 36950765

37

Epigenetic control of skin immunity.

Shibata S. Shibata S. Immunol Med. 2023 Jun;46(2):62-68. doi: 10.1080/25785826.2023.2170087. Epub 2023 Jan 27. Immunol Med. 2023. PMID: 36705253 Review.

38

Baseline erythrocyte sedimentation rate level predicts long-term inhibition of radiographic progression by tocilizumab: the KURAMA cohort.

Watanabe R, Murakami K, Fujisaki T, Ito H, Murata K, Yamamoto W, Fujii T, Onizawa H, Onishi A, Tanaka M, Morinobu A, Hashimoto M. Watanabe R, et al. Immunol Med. 2023 Jun;46(2):84-92. doi: 10.1080/25785826.2023.2170384. Epub 2023 Jan 23. Immunol Med. 2023. PMID: 36688476

39

Smoking and younger age at onset in anti-acetylcholine receptor antibody-positive myasthenia gravis.

Miyazaki Y, Sakushima K, Niino M, Takahashi E, Oiwa K, Naganuma R, Amino I, Akimoto S, Minami N, Yabe I, Kikuchi S. Miyazaki Y, et al. Immunol Med. 2023 Jun;46(2):77-83. doi: 10.1080/25785826.2022.2143077. Epub 2022 Nov 8. Immunol Med. 2023. PMID: 36346077

40

The association between PD-1 gene polymorphisms and susceptibility to multiple sclerosis.

Hassani N, Salmaninejad A, Aslani S, Kamali-Sarvestani E, Vessal M. Hassani N, et al. Immunol Med. 2023 Jun;46(2):69-76. doi: 10.1080/25785826.2022.2137967. Epub 2022 Oct 28. Immunol Med. 2023. PMID: 36308011

41

ASCENIV utilization in a primary immunodeficiency patient with recurrent viral infections.

Rosenbach KP, Greener BN, Rosenbach JT, Wetzstein GA. Rosenbach KP, et al. Immunol Med. 2023 Mar;46(1):58-60. doi: 10.1080/25785826.2022.2151170. Epub 2022 Dec 23. Immunol Med. 2023. PMID: 36562473

42

Correction.

[No authors listed] [No authors listed] Immunol Med. 2023 Mar;46(1):61. doi: 10.1080/25785826.2023.2152540. Epub 2022 Nov 29. Immunol Med. 2023. PMID: 36444674 No abstract available.

43

Physician awareness and understanding of primary immunodeficiency disorders: a web-based study in Japan.

Imai K, Oh A, Morishita A, Inoue Y. Imai K, et al. Immunol Med. 2023 Mar;46(1):45-57. doi: 10.1080/25785826.2022.2137966. Epub 2022 Nov 4. Immunol Med. 2023. PMID: 36330855

44

New insights into the metabolism of Th17 cells.

Kono M. Kono M. Immunol Med. 2023 Mar;46(1):15-24. doi: 10.1080/25785826.2022.2140503. Epub 2022 Nov 3. Immunol Med. 2023. PMID: 36326754 Review.

45

Murine models of idiopathic inflammatory myopathy.

Konishi R, Ichimura Y, Okiyama N. Konishi R, et al. Immunol Med. 2023 Mar;46(1):9-14. doi: 10.1080/25785826.2022.2137968. Epub 2022 Oct 25. Immunol Med. 2023. PMID: 36282924 Review.

46

Association of TLR2 and TLR9 gene polymorphisms with atopic dermatitis: a systematic review and meta-analysis with trial sequential analysis.

Zhou B, Liang S, Shang S, Li L. Zhou B, et al. Immunol Med. 2023 Mar;46(1):32-44. doi: 10.1080/25785826.2022.2132683. Epub 2022 Oct 13. Immunol Med. 2023. PMID: 36237117

47

Homeostasis and immunological function of self-driven memory-phenotype CD4⁺ T lymphocytes.

Kawabe T. Kawabe T. Immunol Med. 2023 Mar;46(1):1-8. doi: 10.1080/25785826.2022.2129370. Epub 2022 Oct 11. Immunol Med. 2023. PMID: 36218322 Review.

48

Thymus variants on imaging of patients with primary Sjögren's syndrome and polymyositis/dermatomyositis: clinical and immunological significance.

Murata O, Suzuki K, Takeuchi T. Murata O, et al. Immunol Med. 2023 Mar;46(1):25-31. doi: 10.1080/25785826.2022.2129371. Epub 2022 Oct 6. Immunol Med. 2023. PMID: 36200743

49

Immune response induced in rodents by anti-CoVid19 plasmid DNA vaccine via pyro-drive jet injector inoculation.

Nishikawa T, Chang CY, Tai JA, Hayashi H, Sun J, Torii S, Ono C, Matsuura Y, Ide R, Mineno J, Sasai M, Yamamoto M, Nakagami H, Yamashita K. Nishikawa T, et al. Immunol Med. 2022 Dec;45(4):251-264. doi: 10.1080/25785826.2022.2111905. Epub 2022 Aug 24. Immunol Med. 2022. PMID: 36001011

50

Serum B cell activating factor (BAFF) as a biomarker for induction of remission with rituximab in ANCA-associated vasculitis.

Tsuboi K, Noguchi K, Kitano M, Furukawa T, Hashimoto T, Azuma N, Matsui K. Tsuboi K, et al. Immunol Med. 2022 Dec;45(4):238-243. doi: 10.1080/25785826.2022.2094592. Epub 2022 Jul 8. Immunol Med. 2022. PMID: 35802795

51

Istradefylline, an adenosine A2a receptor antagonist, inhibits the CD4⁺ T-cell hypersecretion of IL-17A and IL-8 in humans.

Tokano M, Kawano M, Takagi R, Matsushita S. Tokano M, et al. Immunol Med. 2022 Dec;45(4):244-250. doi: 10.1080/25785826.2022.2094593. Epub 2022 Jul 5. Immunol Med. 2022. PMID: 35790489

52

Immunouniverse of SARS-CoV-2.

Jiménez D, Torres Arias M. Jiménez D, et al. Immunol Med. 2022 Dec;45(4):186-224. doi: 10.1080/25785826.2022.2066251. Epub 2022 May 2. Immunol Med. 2022. PMID: 35502127 Review.

53

Safety, efficacy, and immunogenicity of COVID-19 vaccines; a systematic review.

Asghar N, Mumtaz H, Syed AA, Eqbal F, Maharjan R, Bamboria A, Shrehta M. Asghar N, et al. Immunol Med. 2022 Dec;45(4):225-237. doi: 10.1080/25785826.2022.2068331. Epub 2022 May 1. Immunol Med. 2022. PMID: 35491898 Review.

54

Clinical use of anti-histone antibodies in idiopathic and drug-induced lupus.

Lee AYS. Lee AYS. Immunol Med. 2022 Dec;45(4):180-185. doi: 10.1080/25785826.2022.2060168. Epub 2022 Apr 6. Immunol Med. 2022. PMID: 35383534 Review.

55

Signaling via dopamine and adenosine receptors modulate viral peptide-specific and T-cell IL-8 response in COVID-19.

Tokano M, Takagi R, Kawano M, Maesaki S, Tarumoto N, Matsushita S. Tokano M, et al. Immunol Med. 2022 Sep;45(3):162-167. doi: 10.1080/25785826.2022.2079369. Epub 2022 May 27. Immunol Med. 2022. PMID: 35623041

56

Immune-mediated necrotizing myopathy which showed deposition of C5b-9 in the necrotic muscle fibers and was successfully treated with intensive combined therapy with high-dose glucocorticoids, tacrolimus, and intravenous immunoglobulins.

Shimada T, Higashida-Konishi M, Akiyama M, Hama S, Izumi K, Matsubara S, Oshima H, Okano Y. Shimada T, et al. Immunol Med. 2022 Sep;45(3):175-179. doi: 10.1080/25785826.2022.2060169. Epub 2022 Apr 7. Immunol Med. 2022. PMID: 35389818

57

Comparison of complications during 1-year follow-up between remitting seronegative symmetrical synovitis with pitting edema syndrome and elderly-onset rheumatoid arthritis.

Origuchi T, Umeda M, Koga T, Kawashiri SY, Iwamoto N, Ichinose K, Tamai M, Tsukada T, Miyashita T, Iwanaga N, Horai Y, Arima K, Aramaki T, Ueki Y, Eguchi K, Kawakami A. Origuchi T, et al. Immunol Med. 2022 Sep;45(3):168-174. doi: 10.1080/25785826.2022.2046307. Epub 2022 Apr 2. Immunol Med. 2022. PMID: 35369853

58

Lessons from transmissible cancers for immunotherapy and transplant.

Silva RCMC, Panis C, Pires BRB. Silva RCMC, et al. Immunol Med. 2022 Sep;45(3):146-161. doi: 10.1080/25785826.2021.2018783. Epub 2021 Dec 28. Immunol Med. 2022. PMID: 34962854 Review.

59

Radiotherapy driven immunomodulation of the tumor microenvironment and its impact on clinical outcomes: a promising new treatment paradigm.

Mahmood U. Mahmood U. Immunol Med. 2022 Sep;45(3):136-145. doi: 10.1080/25785826.2021.1997268. Epub 2021 Oct 27. Immunol Med. 2022. PMID: 34705597 Review.

60

Management of inflammatory bowel disease during the COVID-19 pandemic.

Hisamatsu T. Hisamatsu T. Immunol Med. 2022 Sep;45(3):128-135. doi: 10.1080/25785826.2021.1978205. Epub 2021 Sep 16. Immunol Med. 2022. PMID: 34530694 Review.

61

Interactomic inhibition of Eomes in the nucleus alleviates EAE via blocking the conversion of Th17 cells into non-classic Th1 cells.

Shin BY, Lee SH, Kim Y, An J, Park TY, Lee SK. Shin BY, et al. Immunol Med. 2022 Jun;45(2):119-127. doi: 10.1080/25785826.2022.2031812. Epub 2022 Feb 7. Immunol Med. 2022. PMID: 35130134

62

The role of toll-like receptors in peptic ulcer disease.

Jin S, Nepal N, Gao Y. Jin S, et al. Immunol Med. 2022 Jun;45(2):69-78. doi: 10.1080/25785826.2021.1963190. Epub 2021 Oct 16. Immunol Med. 2022. PMID: 34657578 Review.

63

Immunopathological basis of immune-related adverse events induced by immune checkpoint blockade therapy.

Kubo T, Hirohashi Y, Tsukahara T, Kanaseki T, Murata K, Morita R, Torigoe T. Kubo T, et al. Immunol Med. 2022 Jun;45(2):108-118. doi: 10.1080/25785826.2021.1976942. Epub 2021 Sep 19. Immunol Med. 2022. PMID: 34542015 Review.

64

Role of CD4⁺CD25⁺FOXP3⁺ T_Reg cells on tumor immunity.

Hariyanto AD, Permata TBM, Gondhowiardjo SA. Hariyanto AD, et al. Immunol Med. 2022 Jun;45(2):94-107. doi: 10.1080/25785826.2021.1975228. Epub 2021 Sep 8. Immunol Med. 2022. PMID: 34495808 Review.

65

Obstetric anti-phospholipid syndrome: from pathogenesis to treatment.

Kaneko K, Ozawa N, Murashima A. Kaneko K, et al. Immunol Med. 2022 Jun;45(2):79-93. doi: 10.1080/25785826.2021.1969116. Epub 2021 Sep 1. Immunol Med. 2022. PMID: 34470570 Review.

66

The impact of maternal exposure to antibiotics on the development of child gut microbiome.

Miyoshi J, Hisamatsu T. Miyoshi J, et al. Immunol Med. 2022 Jun;45(2):63-68. doi: 10.1080/25785826.2021.1963189. Epub 2021 Aug 15. Immunol Med. 2022. PMID: 34392799 Review.

67

B-cell depletion therapy for multiple sclerosis.

Miyazaki Y, Niino M. Miyazaki Y, et al. Immunol Med. 2022 Jun;45(2):54-62. doi: 10.1080/25785826.2021.1952543. Epub 2021 Jul 21. Immunol Med. 2022. PMID: 34289331 Review.

68

New mimic of relapse or regional lymph node metastasis in a cancer survivor: a case of mRNA COVID-19 vaccine-induced lymphadenitis with high FDG uptake.

Tsumura Y, Asakura K, Takahashi I, Akaihata M, Takahashi Y, Ishida Y. Tsumura Y, et al. Immunol Med. 2022 Mar;45(1):45-47. doi: 10.1080/25785826.2021.1999786. Epub 2021 Dec 16. Immunol Med. 2022. PMID: 34915816

69

Emerging role of leptin in joint inflammation and destruction.

Tsuchiya H, Fujio K. Tsuchiya H, et al. Immunol Med. 2022 Mar;45(1):27-34. doi: 10.1080/25785826.2021.1948689. Epub 2021 Aug 6. Immunol Med. 2022. PMID: 34362290 Review.

70

Characteristics and management of ocular sarcoidosis.

Takase H. Takase H. Immunol Med. 2022 Mar;45(1):12-21. doi: 10.1080/25785826.2021.1940740. Epub 2021 Jul 2. Immunol Med. 2022. PMID: 34214013 Review.

71

Arthritis-associated osteoclastogenic macrophages (AtoMs) participate in pathological bone erosion in rheumatoid arthritis.

Agemura T, Hasegawa T, Yari S, Kikuta J, Ishii M. Agemura T, et al. Immunol Med. 2022 Mar;45(1):22-26. doi: 10.1080/25785826.2021.1944547. Epub 2021 Jun 30. Immunol Med. 2022. PMID: 34187325 Review.

72

Adaptive immunity in the joint of rheumatoid arthritis.

Yamada H. Yamada H. Immunol Med. 2022 Mar;45(1):1-11. doi: 10.1080/25785826.2021.1930371. Epub 2021 May 30. Immunol Med. 2022. PMID: 34053404 Review.

73

Anti-interferon-gamma autoantibody related disseminated nontuberculous mycobacteriosis with pathological features of immunoglobulin G4-related disease.

Nagamura N, Imada T. Nagamura N, et al. Immunol Med. 2022 Mar;45(1):48-53. doi: 10.1080/25785826.2021.1914962. Epub 2021 May 25. Immunol Med. 2022. PMID: 34033731

74

Prevalence and predictive factors of difficult-to-treat rheumatoid arthritis: the KURAMA cohort.

Watanabe R, Hashimoto M, Murata K, Murakami K, Tanaka M, Ohmura K, Ito H, Matsuda S. Watanabe R, et al. Immunol Med. 2022 Mar;45(1):35-44. doi: 10.1080/25785826.2021.1928383. Epub 2021 May 25. Immunol Med. 2022. PMID: 34033729 Free article.

75

Updating the pathophysiology of arthritic bone destruction: identifying and visualizing pathological osteoclasts in pannus.

Hasegawa T. Hasegawa T. Immunol Med. 2021 Dec;44(4):246-251. doi: 10.1080/25785826.2021.1913883. Epub 2021 May 19. Immunol Med. 2021. PMID: 34010590 Review.

76

Clinical manifestations in anti-Ro52/SS-A antibody-seropositive patients with Sjögren's syndrome.

Nakamura H, Morimoto S, Shimizu T, Takatani A, Nishihata SY, Kawakami A. Nakamura H, et al. Immunol Med. 2021 Dec;44(4):252-262. doi: 10.1080/25785826.2021.1919342. Epub 2021 May 14. Immunol Med. 2021. PMID: 33989125

77

Macrophage activation syndrome in systemic juvenile idiopathic arthritis.

Shimizu M. Shimizu M. Immunol Med. 2021 Dec;44(4):237-245. doi: 10.1080/25785826.2021.1912893. Epub 2021 May 13. Immunol Med. 2021. PMID: 33982649

78

Study on hypoxia-inducible factor and its roles in immune system.

Kiani AA, Elyasi H, Ghoreyshi S, Nouri N, Safarzadeh A, Nafari A. Kiani AA, et al. Immunol Med. 2021 Dec;44(4):223-236. doi: 10.1080/25785826.2021.1910187. Epub 2021 Apr 25. Immunol Med. 2021. PMID: 33896415 Review.

79

Anti-complement factor H (CFH) antibodies and a novel CFH gene mutation in an atypical hemolytic uremic syndrome patient with complement activation of the classical pathway.

Minato S, Iijima H, Nakao H, Nishi K, Hidaka Y, Inoue N, Kubota M, Ishiguro A. Minato S, et al. Immunol Med. 2021 Dec;44(4):274-277. doi: 10.1080/25785826.2021.1905303. Epub 2021 Mar 30. Immunol Med. 2021. PMID: 33784485

80

Black-blood magnetic resonance imaging suggesting central nervous system vasculitis in moyamoya syndrome associated with systemic lupus erythematosus.

Kadoba K, Nishimura K, Waki D, Okada T, Kumazawa T, Saito R, Murabe H, Yokota T. Kadoba K, et al. Immunol Med. 2021 Dec;44(4):270-273. doi: 10.1080/25785826.2021.1878728. Epub 2021 Feb 17. Immunol Med. 2021. PMID: 33595418

81

B cell targeted therapy for immunoglobulin G4-related disease.

Yamamoto M. Yamamoto M. Immunol Med. 2021 Dec;44(4):216-222. doi: 10.1080/25785826.2021.1886630. Epub 2021 Feb 14. Immunol Med. 2021. PMID: 33583344

82

A case of pulmonary arterial hypertension complicated by anti-neutrophil cytoplasmic antibody-associated vasculitis and systemic sclerosis.

Yoshifuji H, Kagebayashi S, Kinoshita H, Fujii T, Okano Y, Katsushima M, Mimori T. Yoshifuji H, et al. Immunol Med. 2021 Dec;44(4):263-269. doi: 10.1080/25785826.2021.1874137. Epub 2021 Jan 15. Immunol Med. 2021. PMID: 33449872 Free article.

83

Regulation of T cell differentiation by the AP-1 transcription factor JunB.

Katagiri T, Kameda H, Nakano H, Yamazaki S. Katagiri T, et al. Immunol Med. 2021 Sep;44(3):197-203. doi: 10.1080/25785826.2021.1872838. Epub 2021 Jan 20. Immunol Med. 2021. PMID: 33470914 Review.

84

Macrophages as a source of fibrosis biomarkers for non-alcoholic fatty liver disease.

Yoshio S, Kanto T. Yoshio S, et al. Immunol Med. 2021 Sep;44(3):175-186. doi: 10.1080/25785826.2020.1868664. Epub 2021 Jan 14. Immunol Med. 2021. PMID: 33444517

85

Immune response to COVID-19 infection: a double-edged sword.

Saad N, Moussa S. Saad N, et al. Immunol Med. 2021 Sep;44(3):187-196. doi: 10.1080/25785826.2020.1870305. Epub 2021 Jan 14. Immunol Med. 2021. PMID: 33444511 Review.

86

Low incidence of intrauterine growth restriction in pregnant patients with systemic lupus erythematosus taking hydroxychloroquine.

Canti V, Scarrone M, De Lorenzo R, Ramirez GA, Erra R, Bordoli S, Cella S, Schmit E, Rosa S, Castiglioni MT, Rovere-Querini P. Canti V, et al. Immunol Med. 2021 Sep;44(3):204-210. doi: 10.1080/25785826.2020.1868652. Epub 2021 Jan 8. Immunol Med. 2021. PMID: 33417532

87

Protein kinase 2 (CK2): a potential regulator of immune cell development and function in cancer.

Husain K, Williamson TT, Nelson N, Ghansah T. Husain K, et al. Immunol Med. 2021 Sep;44(3):159-174. doi: 10.1080/25785826.2020.1843267. Epub 2020 Nov 9. Immunol Med. 2021. PMID: 33164702

88

An overview of sex and reproductive immunity from an evolutionary/anthropological perspective.

Araki Y, Yoshitake H, Yamatoya K, Fujiwara H. Araki Y, et al. Immunol Med. 2021 Sep;44(3):152-158. doi: 10.1080/25785826.2020.1831219. Epub 2020 Oct 11. Immunol Med. 2021. PMID: 33043824 Review.

89

Potential of B-cell-targeting therapy in overcoming multidrug resistance and tissue invasiveness associated with P-glycoprotein expressing-B cell compartments.

Tsujimura S, Tanaka Y. Tsujimura S, et al. Immunol Med. 2021 Sep;44(3):142-151. doi: 10.1080/25785826.2020.1825276. Epub 2020 Oct 5. Immunol Med. 2021. PMID: 33017281

90

Tsukamurella pulmonis central venous catheter infection mimicking proteinase 3-antineutrophil cytoplasmic antibody (PR3-ANCA)-associated vasculitis.

Ochi K, Mukai T, Ota S, Hiraiwa C, Ikeda M, Ikeda A, Oda T, Yamamoto Y, Ueki T. Ochi K, et al. Immunol Med. 2021 Sep;44(3):211-215. doi: 10.1080/25785826.2020.1791403. Epub 2020 Jul 10. Immunol Med. 2021. PMID: 32649848

91

Exosomes-based cell-free cancer therapy: a novel strategy for targeted therapy.

Dutta A. Dutta A. Immunol Med. 2021 Jun;44(2):116-123. doi: 10.1080/25785826.2020.1818482. Epub 2020 Sep 14. Immunol Med. 2021. PMID: 32924880 Review.

92

Harmful and beneficial effects of inflammatory response on reproduction: sterile and pathogen-associated inflammation.

Negishi Y, Shima Y, Takeshita T, Morita R. Negishi Y, et al. Immunol Med. 2021 Jun;44(2):98-115. doi: 10.1080/25785826.2020.1809951. Epub 2020 Aug 24. Immunol Med. 2021. PMID: 32838688 Review.

93

Evaluation of disease activity in uveoretinitis associated with Behçet's disease.

Keino H. Keino H. Immunol Med. 2021 Jun;44(2):86-97. doi: 10.1080/25785826.2020.1800244. Epub 2020 Jul 29. Immunol Med. 2021. PMID: 32726184 Review.

94

Allelic polymorphisms of KIRs and antitumor immunity against chronic myeloid leukemia.

Shindo T, Ureshino H, Kojima H, Tanaka H, Kimura S. Shindo T, et al. Immunol Med. 2021 Jun;44(2):61-68. doi: 10.1080/25785826.2020.1796062. Epub 2020 Jul 25. Immunol Med. 2021. PMID: 32715973 Review.

95

Autoimmune gastrointestinal dysmotility: the interface between clinical immunology and neurogastroenterology.

Nakane S, Mukaino A, Ihara E, Ogawa Y. Nakane S, et al. Immunol Med. 2021 Jun;44(2):74-85. doi: 10.1080/25785826.2020.1797319. Epub 2020 Jul 27. Immunol Med. 2021. PMID: 32715927 Review.

96

Anti-DNA antibodies cross-reactive with β₂-glycoprotein I induce monocyte tissue factor through the TLR9 pathway.

Saito M, Makino Y, Inoue K, Watanabe Y, Hoshi O, Kubota T. Saito M, et al. Immunol Med. 2021 Jun;44(2):124-135. doi: 10.1080/25785826.2020.1796285. Epub 2020 Jul 23. Immunol Med. 2021. PMID: 32701417

97

CAR T cell therapy.

Hosen N. Hosen N. Immunol Med. 2021 Jun;44(2):69-73. doi: 10.1080/25785826.2020.1796063. Epub 2020 Jul 21. Immunol Med. 2021. PMID: 32693699 Review.

98

Fatal fulminant hepatitis induced by combined ipilimumab and nivolumab therapy despite favorable histologic response and confirmed by autopsy in a patient with clear cell renal cell carcinoma.

Kubo T, Sugawara T, Shinkawa T, Kurisu T, Kouzen N, Tanaka T, Fukuta F, Yamasaki K, Sugita S, Matsuo K, Morita R, Hirohashi Y, Tsukahara T, Kanaseki T, Hasegawa T, Masumori N, Torigoe T. Kubo T, et al. Immunol Med. 2021 Jun;44(2):136-141. doi: 10.1080/25785826.2020.1788229. Epub 2020 Jul 7. Immunol Med. 2021. PMID: 32634346

99

Immunoinformatics design of multiepitopes peptide-based universal cancer vaccine using matrix metalloproteinase-9 protein as a target.

Abdelmoneim AH, Mustafa MI, Abdelmageed MI, Murshed NS, Dawoud ED, Ahmed EM, Kamal Eldein RM, Elfadol NM, Sati AOM, Makhawi AM. Abdelmoneim AH, et al. Immunol Med. 2021 Mar;44(1):35-52. doi: 10.1080/25785826.2020.1794165. Epub 2020 Jul 21. Immunol Med. 2021. PMID: 32692610

100

Fecal microbiota transplantation for ulcerative colitis.

Matsuoka K. Matsuoka K. Immunol Med. 2021 Mar;44(1):30-34. doi: 10.1080/25785826.2020.1792040. Epub 2020 Jul 14. Immunol Med. 2021. PMID: 32663072 Review.

101

Transcriptional intermediary factor 1 (TIF1) and anti-TIF1γ antibody-positive dermatomyositis.

Kotobuki Y, Tonomura K, Fujimoto M. Kotobuki Y, et al. Immunol Med. 2021 Mar;44(1):23-29. doi: 10.1080/25785826.2020.1791402. Epub 2020 Jul 10. Immunol Med. 2021. PMID: 32649853 Review.

102

Severe oral stomatitis due to reactivation of herpes simplex virus type 1 in a methotrexate-treated patient with dermatomyositis.

Akagi T, Mukai T, Fujita S, Yamamoto T, Fukuda M, Morita Y. Akagi T, et al. Immunol Med. 2021 Mar;44(1):56-60. doi: 10.1080/25785826.2020.1787585. Epub 2020 Jul 10. Immunol Med. 2021. PMID: 32649847

103

Developmental process in diffuse psychological/neuropsychiatric manifestations of neuropsychiatric systemic lupus erythematosus.

Arinuma Y, Yamaoka K. Arinuma Y, et al. Immunol Med. 2021 Mar;44(1):16-22. doi: 10.1080/25785826.2020.1791401. Epub 2020 Jul 10. Immunol Med. 2021. PMID: 32649846 Review.

104

Towards the era of immune checkpoint inhibitors and personalized cancer immunotherapy.

Nakajima H, Nakatsura T. Nakajima H, et al. Immunol Med. 2021 Mar;44(1):10-15. doi: 10.1080/25785826.2020.1785654. Epub 2020 Jul 9. Immunol Med. 2021. PMID: 32643578 Review.

105

A case of anti-BP230 antibody-positive bullous pemphigoid receiving DPP-4 inhibitor.

Sawada K, Sawada T, Kobayashi T, Fujiki A, Matsushita T, Kawara S, Izumi K, Nishie W, Shimizu H, Takehara K, Hamaguchi Y. Sawada K, et al. Immunol Med. 2021 Mar;44(1):53-55. doi: 10.1080/25785826.2020.1787584. Epub 2020 Jul 7. Immunol Med. 2021. PMID: 32634333

106

T follicular helper cell subsets: a potential key player in autoimmunity.

Kurata I, Matsumoto I, Sumida T. Kurata I, et al. Immunol Med. 2021 Mar;44(1):1-9. doi: 10.1080/25785826.2020.1776079. Epub 2020 Jun 17. Immunol Med. 2021. PMID: 32546108 Review.

107

Cow milk exosomes activate NK cells and γδT cells in human PBMCs in vitro.

Komine-Aizawa S, Ito S, Aizawa S, Namiki T, Hayakawa S. Komine-Aizawa S, et al. Immunol Med. 2020 Dec;43(4):161-170. doi: 10.1080/25785826.2020.1791400. Epub 2020 Jul 10. Immunol Med. 2020. PMID: 32649844

108

CXCL13-producing PD-1^hiCXCR5^- helper T cells in chronic inflammation.

Yoshitomi H. Yoshitomi H. Immunol Med. 2020 Dec;43(4):156-160. doi: 10.1080/25785826.2020.1781998. Epub 2020 Jun 25. Immunol Med. 2020. PMID: 32584200 Review.

109

JAK inhibitors for the treatment of rheumatoid arthritis.

Morinobu A. Morinobu A. Immunol Med. 2020 Dec;43(4):148-155. doi: 10.1080/25785826.2020.1770948. Epub 2020 Jun 5. Immunol Med. 2020. PMID: 32501149 Review.

110

Diversity of neuropsychiatric manifestations in systemic lupus erythematosus.

Fujieda Y. Fujieda Y. Immunol Med. 2020 Dec;43(4):135-141. doi: 10.1080/25785826.2020.1770947. Epub 2020 May 27. Immunol Med. 2020. PMID: 32459601 Review.

111

Basic mechanism of immune system activation by mitochondria.

Iwasaki Y, Takeshima Y, Fujio K. Iwasaki Y, et al. Immunol Med. 2020 Dec;43(4):142-147. doi: 10.1080/25785826.2020.1756609. Epub 2020 May 12. Immunol Med. 2020. PMID: 32393116 Review.

112

A case of complete atrioventricular block in secondary hemophagocytic syndrome/hemophagocytic lymphohistiocytosis recovered by plasma exchange and cytokine absorbing therapy with AN69ST continuous hemodiafiltration.

Harano Y, Ishikawa Y, Hattori K, Ichinose M, Tomofuji Y, Okano H, Owada G, Kimura Y, Nanao T, Fujimoto J, Nishizawa H, Iioka Y, Osada J, Fujiwara M, Kita Y. Harano Y, et al. Immunol Med. 2020 Dec;43(4):171-178. doi: 10.1080/25785826.2020.1761145. Epub 2020 May 6. Immunol Med. 2020. PMID: 32374660

113

Interleukin-22 promotes the migration and invasion of oral squamous cell carcinoma cells.

Komine-Aizawa S, Aizawa S, Takano C, Hayakawa S. Komine-Aizawa S, et al. Immunol Med. 2020 Sep;43(3):121-129. doi: 10.1080/25785826.2020.1775060. Epub 2020 Jun 16. Immunol Med. 2020. PMID: 32546118

114

Osteocalcin and regulatory cytokine imbalance in children with congenital cleft lip and palate.

Nesterova I, Mitropanova M, Chudilova G, Lomtatidze L. Nesterova I, et al. Immunol Med. 2020 Sep;43(3):130-134. doi: 10.1080/25785826.2020.1775465. Epub 2020 Jun 8. Immunol Med. 2020. PMID: 32511082

115

Non-TNF inhibitor switchers versus TNF inhibitor cyclers from multicentre rheumatoid arthritis ultrasonography prospective cohort in Japan.

Endo Y, Kawashiri SY, Morimoto S, Nishino A, Okamoto M, Tsuji S, Takatani A, Shimizu T, Sumiyoshi R, Igawa T, Koga T, Iwamoto N, Ichinose K, Tamai M, Nakamura H, Origuchi T, Ueki Y, Yoshitama T, Eiraku N, Matsuoka N, Okada A, Fujikawa K, Hamada H, Tsuru T, Nagano S, Arinobu Y, Hidaka T, Tada Y, Kawakami A. Endo Y, et al. Immunol Med. 2020 Sep;43(3):115-120. doi: 10.1080/25785826.2020.1757920. Epub 2020 May 12. Immunol Med. 2020. PMID: 32393150

116

'Narrow-sense' and 'broad-sense' vascular abnormalities of systemic sclerosis.

Jinnin M. Jinnin M. Immunol Med. 2020 Sep;43(3):107-114. doi: 10.1080/25785826.2020.1754692. Epub 2020 Apr 23. Immunol Med. 2020. PMID: 32324110 Review.

117

The approach to precision medicine for the treatment of psoriatic arthritis.

Miyagawa I, Tanaka Y. Miyagawa I, et al. Immunol Med. 2020 Sep;43(3):98-102. doi: 10.1080/25785826.2020.1753430. Epub 2020 Apr 20. Immunol Med. 2020. PMID: 32306849 Review.

118

Basic and clinical associations between bone and cancer.

He F, Matsumoto Y. He F, et al. Immunol Med. 2020 Sep;43(3):103-106. doi: 10.1080/25785826.2020.1754084. Epub 2020 Apr 17. Immunol Med. 2020. PMID: 32301686 Review.

119

New insights into IFN-γ in rheumatoid arthritis: role in the era of JAK inhibitors.

Kato M. Kato M. Immunol Med. 2020 Jun;43(2):72-78. doi: 10.1080/25785826.2020.1751908. Epub 2020 Apr 25. Immunol Med. 2020. PMID: 32338187 Review.

120

Treatment of inflammatory bowel disease from the immunological perspective.

Nakase H. Nakase H. Immunol Med. 2020 Jun;43(2):79-86. doi: 10.1080/25785826.2020.1751934. Epub 2020 Apr 23. Immunol Med. 2020. PMID: 32324112 Review.

121

Dry eye in rheumatoid arthritis: relation to disease activity.

Abd-Allah NM, Hassan AA, Omar G, Hamdy M, Abdelaziz STA, Abd El Hamid WM, Moussa RA. Abd-Allah NM, et al. Immunol Med. 2020 Jun;43(2):92-97. doi: 10.1080/25785826.2020.1729597. Epub 2020 Feb 23. Immunol Med. 2020. PMID: 32089102

122

Antigen specific B cells in myasthenia gravis patients.

Takata K, Kinoshita M, Mochizuki H, Okuno T. Takata K, et al. Immunol Med. 2020 Jun;43(2):65-71. doi: 10.1080/25785826.2020.1724756. Epub 2020 Feb 11. Immunol Med. 2020. PMID: 32046601 Review.

123

Bone dynamics and inflammation: lessons from rare diseases.

Matsumoto Y, Rottapel R. Matsumoto Y, et al. Immunol Med. 2020 Jun;43(2):61-64. doi: 10.1080/25785826.2020.1720104. Epub 2020 Jan 30. Immunol Med. 2020. PMID: 31999934 Review.

124

Abatacept reduces disease activity of rheumatoid arthritis independently of modulating anti-citrullinated peptide antibody production.

Yamada H, Tsuru T, Otsuka T, Maekawa M, Harada H, Fukuda T, Tsukamoto H, Maeyama A, Yoshizawa S, Wada K, Nakashima Y, Shono E, Yoshizawa S, Jojima H, Kondo M. Yamada H, et al. Immunol Med. 2020 Jun;43(2):87-91. doi: 10.1080/25785826.2020.1718833. Epub 2020 Jan 29. Immunol Med. 2020. PMID: 31994996

125

B cells targeting therapy in the management of systemic lupus erythematosus.

Lee WS, Amengual O. Lee WS, et al. Immunol Med. 2020 Mar;43(1):16-35. doi: 10.1080/25785826.2019.1698929. Epub 2019 Dec 9. Immunol Med. 2020. PMID: 32107989

126

Efficacy of PD-1 blockade therapy and T cell immunity in lung cancer patients.

Kagamu H, Kaira K. Kagamu H, et al. Immunol Med. 2020 Mar;43(1):10-15. doi: 10.1080/25785826.2019.1710427. Epub 2020 Jan 10. Immunol Med. 2020. PMID: 31923366

127

Clinical usefulness of anti-M-type phospholipase-A-receptor antibodies in patients with membranous nephropathy and the comparison of three quantification methods.

Katsumata Y, Okamoto Y, Moriyama T, Moriyama R, Kawamoto M, Hanaoka M, Uchida K, Nitta K, Harigai M. Katsumata Y, et al. Immunol Med. 2020 Mar;43(1):47-56. doi: 10.1080/25785826.2019.1710079. Epub 2020 Jan 7. Immunol Med. 2020. PMID: 31910103

128

An eight-year-old girl with autoimmune polyglandular syndrome type3A that developed during the course of primary Epstein-Barr virus (EBV) infection: clinical implication of EBV in autoimmune thyroid disease.

Kirino S, Nakatani H, Honma A, Shinbo A, Onda K, Okada M, Imai M, Suzuki N, Oshiba A, Nagasawa M. Kirino S, et al. Immunol Med. 2020 Mar;43(1):57-60. doi: 10.1080/25785826.2019.1701365. Epub 2019 Dec 18. Immunol Med. 2020. PMID: 31852362

129

Oxidative stress in CLL patients leads to activation of Th9 cells: an experimental and comprehensive survey.

Sabry SA, El-Senduny FF, Abousamra NK, Salah El-Din M, Youssef MM. Sabry SA, et al. Immunol Med. 2020 Mar;43(1):36-46. doi: 10.1080/25785826.2019.1700747. Epub 2019 Dec 12. Immunol Med. 2020. PMID: 31829825

130

Memory T cell, exhaustion, and tumor immunity.

Ando M, Ito M, Srirat T, Kondo T, Yoshimura A. Ando M, et al. Immunol Med. 2020 Mar;43(1):1-9. doi: 10.1080/25785826.2019.1698261. Epub 2019 Dec 10. Immunol Med. 2020. PMID: 31822213 Review.

131

Pharmacokinetic properties of Privigen^® in Japanese patients with primary immunodeficiency.

Morio T, Baheti G, Tortorici MA, Hofmann J, Rojavin MA. Morio T, et al. Immunol Med. 2019 Dec;42(4):162-168. doi: 10.1080/25785826.2019.1700085. Epub 2019 Dec 17. Immunol Med. 2019. PMID: 31847720 Clinical Trial.

132

Successful treatment of a patient with refractory immune thrombocytopenic purpura in systemic lupus erythematosus with rituximab.

Abe K, Ishikawa Y, Ishikawa J, Fujiwara M, Kita Y. Abe K, et al. Immunol Med. 2019 Dec;42(4):185-188. doi: 10.1080/25785826.2019.1696644. Epub 2019 Dec 3. Immunol Med. 2019. PMID: 31794352

133

Role of eosinophils in protective immunity against secondary nematode infections.

Yasuda K, Kuroda E. Yasuda K, et al. Immunol Med. 2019 Dec;42(4):148-155. doi: 10.1080/25785826.2019.1697135. Epub 2019 Dec 3. Immunol Med. 2019. PMID: 31794348 Review.

134

Diagnostic approach for patients with unidentified fever according to the classical criteria of fever of unknown origin in the field of autoimmune disorders.

Watanabe R, Sakuraba H, Hiraga H, Kishida D, Ota S, Hasui K, Kikuchi H, Akemoto Y, Tanaka N, Maeda T, Murai Y, Yoshida S, Tatsuta T, Sawaya M, Chinda D, Mikami T, Ishiguro Y, Fukuda S. Watanabe R, et al. Immunol Med. 2019 Dec;42(4):176-184. doi: 10.1080/25785826.2019.1696631. Epub 2019 Dec 1. Immunol Med. 2019. PMID: 31790331

135

Recent findings regarding the effects of microRNAs on fibroblast-like synovial cells in rheumatoid arthritis.

Iwamoto N, Kawakami A. Iwamoto N, et al. Immunol Med. 2019 Dec;42(4):156-161. doi: 10.1080/25785826.2019.1695490. Epub 2019 Nov 26. Immunol Med. 2019. PMID: 31770498 Review.

136

Prognostic value of IL-34 in colorectal cancer patients.

Kobayashi T, Baghdadi M, Han N, Murata T, Hama N, Otsuka R, Wada H, Shiozawa M, Yokose T, Miyagi Y, Takano A, Daigo Y, Seino KI. Kobayashi T, et al. Immunol Med. 2019 Dec;42(4):169-175. doi: 10.1080/25785826.2019.1691429. Epub 2019 Nov 23. Immunol Med. 2019. PMID: 31762401

137

Long-term maintenance of the mucosal healing induced by azacitidine therapy in a patient with intestinal Behçet's-like disease accompanied with myelodysplastic syndrome involving trisomy 8.

Tanaka N, Sakuraba H, Hiraga H, Mayama K, Kikuchi H, Kishida D, Akemoto Y, Hasui K, Ota S, Watanabe R, Murai Y, Maeda T, Kamata K, Tatsuta T, Sawaya M, Chinda D, Mikami T, Yamagata K, Ishiguro Y, Tanaka M, Fukuda S. Tanaka N, et al. Immunol Med. 2019 Sep;42(3):135-141. doi: 10.1080/25785826.2019.1687251. Epub 2019 Nov 9. Immunol Med. 2019. PMID: 31707933

138

Current standardized therapeutic approach for uveitis in Japan.

Maruyama K. Maruyama K. Immunol Med. 2019 Sep;42(3):124-134. doi: 10.1080/25785826.2019.1678961. Epub 2019 Oct 24. Immunol Med. 2019. PMID: 31645201 Review.

139

A case of celiac disease with type I enteropathy-associated T-cell lymphoma in a Japanese male patient.

Hiraga H, Sakuraba H, Tanaka N, Watanabe R, Akemoto Y, Ota S, Kikuchi H, Sawaya M, Hiraga N, Chinda D, Hanabata N, Mikami T, Shimoyama T, Takahata T, Tanaka M, Fukuda S. Hiraga H, et al. Immunol Med. 2019 Sep;42(3):142-147. doi: 10.1080/25785826.2019.1673031. Epub 2019 Oct 11. Immunol Med. 2019. PMID: 31603739

140

Inhibitory B cell co-receptors and autoimmune diseases.

Tsubata T. Tsubata T. Immunol Med. 2019 Sep;42(3):108-116. doi: 10.1080/25785826.2019.1660038. Epub 2019 Sep 18. Immunol Med. 2019. PMID: 31532707 Review.

141

Plasmablasts and neuroimmunological disorders.

Chihara N, Matsumoto R, Yamamura T. Chihara N, et al. Immunol Med. 2019 Sep;42(3):103-107. doi: 10.1080/25785826.2019.1659476. Epub 2019 Aug 29. Immunol Med. 2019. PMID: 31464170 Review.

142

Dynamics and clinical significance of intestinal intraepithelial lymphocytes.

Sumida H. Sumida H. Immunol Med. 2019 Sep;42(3):117-123. doi: 10.1080/25785826.2019.1658516. Epub 2019 Aug 27. Immunol Med. 2019. PMID: 31453756 Review.

143

Analysis of the mechanism underlying liver diseases using human induced pluripotent stem cells.

Kakinuma S, Watanabe M. Kakinuma S, et al. Immunol Med. 2019 Jun;42(2):71-78. doi: 10.1080/25785826.2019.1657254. Epub 2019 Sep 9. Immunol Med. 2019. PMID: 31498713 Review.

144

Unusual manifestations of giant cell arteritis and granulomatosis with polyangiitis.

Yoshimoto R, Tanaka K, Kawahata T, Takatori S, Takatori K, Eguchi K, Fujishiro D, Kodama S, Kobayashi A, Okamoto K, Yuzawa S, Ota T, Makino Y. Yoshimoto R, et al. Immunol Med. 2019 Jun;42(2):94-98. doi: 10.1080/25785826.2019.1657377. Epub 2019 Aug 30. Immunol Med. 2019. PMID: 31469613

145

RNA binding proteins in the control of autoimmune diseases.

Yoshinaga M, Takeuchi O. Yoshinaga M, et al. Immunol Med. 2019 Jun;42(2):53-64. doi: 10.1080/25785826.2019.1655192. Epub 2019 Aug 26. Immunol Med. 2019. PMID: 31449478 Review.

146

A case of psoriatic arthritis, with joint involvement preceding skin involvement, successfully treated with adalimumab (80 mg every other week).

Nanke Y, Kobashigawa T, Sugimoto N, Yamanaka H, Kotake S. Nanke Y, et al. Immunol Med. 2019 Jun;42(2):99-102. doi: 10.1080/25785826.2019.1657255. Epub 2019 Aug 25. Immunol Med. 2019. PMID: 31446856

147

Novel topical and systemic therapies in atopic dermatitis.

Suga H, Sato S. Suga H, et al. Immunol Med. 2019 Jun;42(2):84-93. doi: 10.1080/25785826.2019.1642727. Epub 2019 Jul 18. Immunol Med. 2019. PMID: 31318324 Review.

148

Proteogenomics: advances in cancer antigen research.

Kanaseki T, Torigoe T. Kanaseki T, et al. Immunol Med. 2019 Jun;42(2):65-70. doi: 10.1080/25785826.2019.1640500. Epub 2019 Jul 18. Immunol Med. 2019. PMID: 31318319 Review.

149

The effectiveness of adalimumab treatment for non-infectious uveitis.

Hasegawa E, Takeda A, Yawata N, Sonoda KH. Hasegawa E, et al. Immunol Med. 2019 Jun;42(2):79-83. doi: 10.1080/25785826.2019.1642080. Epub 2019 Jul 17. Immunol Med. 2019. PMID: 31315546 Review.

150

Future trends in the treatment of atopic dermatitis.

Igawa K. Igawa K. Immunol Med. 2019 Mar;42(1):10-15. doi: 10.1080/25785826.2019.1628467. Epub 2019 Jun 17. Immunol Med. 2019. PMID: 31204894 Review.

151

Systemic lupus erythematosus and immunodeficiency.

Sawada T, Fujimori D, Yamamoto Y. Sawada T, et al. Immunol Med. 2019 Mar;42(1):1-9. doi: 10.1080/25785826.2019.1628466. Epub 2019 Jun 17. Immunol Med. 2019. PMID: 31204893 Review.

152

A case of neutrophilic dermatosis with MEFV gene variant and abnormal activation of peripheral blood monocytes: a case report.

Otsuka M, Koga T, Sumiyoshi R, Koike Y, Furukawa K, Okamoto M, Endo Y, Tsuji S, Takatani A, Shimizu T, Igawa T, Kawashiri SY, Iwamoto N, Ichinose K, Tamai M, Nakamura H, Origuchi T, Daisuke N, Kawakami A. Otsuka M, et al. Immunol Med. 2019 Mar;42(1):45-49. doi: 10.1080/25785826.2019.1625507. Epub 2019 Jun 16. Immunol Med. 2019. PMID: 31204589

153

Correction.

[No authors listed] [No authors listed] Immunol Med. 2019 Mar;42(1):50-52. doi: 10.1080/25785826.2019.1622207. Epub 2019 Jun 11. Immunol Med. 2019. PMID: 31185828 No abstract available.

154

Dipeptidyl peptidase IV inhibitor-associated bullous pemphigoid: a recently recognized autoimmune blistering disease with unique clinical, immunological and genetic characteristics.

Nishie W. Nishie W. Immunol Med. 2019 Mar;42(1):22-28. doi: 10.1080/25785826.2019.1619233. Epub 2019 Jun 6. Immunol Med. 2019. PMID: 31169082 Review.

155

Multicenter, observational clinical study of abatacept in Japanese patients with rheumatoid arthritis.

Ogawa N, Ohashi H, Ota Y, Kobori K, Suzuki M, Tsuboi S, Hayakawa M, Goto Y, Karahashi T, Kimoto O, Miyamoto T, Furukawa S, Shimoyama K, Suzuki D, Maekawa Y. Ogawa N, et al. Immunol Med. 2019 Mar;42(1):29-38. doi: 10.1080/25785826.2019.1605036. Epub 2019 May 8. Immunol Med. 2019. PMID: 31067155

156

Treatment with indigo naturalis for inflammatory bowel disease and other immune diseases.

Naganuma M. Naganuma M. Immunol Med. 2019 Mar;42(1):16-21. doi: 10.1080/25785826.2019.1599158. Epub 2019 Apr 29. Immunol Med. 2019. PMID: 31034341 Review.

157

A case of nivolumab-associated colitis, which relapsed after mucosal healing and was then successfully treated with mesalazine.

Kikuchi H, Sakuraba H, Akemoto Y, Murai Y, Fukutoku Y, Asari T, Tatsuta T, Hasui K, Hiraga H, Sawaya M, Chinda D, Mikami T, Tanaka M, Fukuda S. Kikuchi H, et al. Immunol Med. 2019 Mar;42(1):39-44. doi: 10.1080/25785826.2019.1580477. Epub 2019 Mar 27. Immunol Med. 2019. PMID: 30917094

158

Diagnosis and treatment of autoinflammatory diseases in adults: a clinical approach from rheumatologists.

Koga T, Kawakami A. Koga T, et al. Immunol Med. 2018 Dec;41(4):177-180. doi: 10.1080/25785826.2018.1524105. Epub 2019 Feb 3. Immunol Med. 2018. PMID: 30714492

159

Clinical and etiological meaning of anti-carbamylated protein antibodies in rheumatoid arthritis.

Nakabo S. Nakabo S. Immunol Med. 2018 Dec;41(4):147-153. doi: 10.1080/25785826.2018.1556017. Epub 2019 Feb 3. Immunol Med. 2018. PMID: 30714481

160

Chronic active Epstein-Barr virus infection: a bi-faceted disease with inflammatory and neoplastic elements.

Arai A. Arai A. Immunol Med. 2018 Dec;41(4):162-169. doi: 10.1080/25785826.2018.1556030. Epub 2019 Jan 31. Immunol Med. 2018. PMID: 30704352

161

Efficacy of infliximab as a switched biologic in rheumatoid arthritis patients in daily clinical practice.

Umeda M, Koga T, Ichinose K, Takatani A, Igawa T, Shimizu T, Fukui S, Nishino A, Horai Y, Hirai Y, Kawashiri SY, Iwamoto N, Tamai M, Nakamura H, Origuchi T, Aramaki T, Ueki Y, Okada A, Fujikawa K, Matsuoka N, Kawakami A. Umeda M, et al. Immunol Med. 2018 Dec;41(4):181-186. doi: 10.1080/25785826.2018.1542942. Epub 2019 Jan 11. Immunol Med. 2018. PMID: 30632931

162

Inflammatory bowel diseases and primary immunodeficiency diseases.

Kanegane H. Kanegane H. Immunol Med. 2018 Dec;41(4):154-161. doi: 10.1080/25785826.2018.1556025. Epub 2019 Jan 11. Immunol Med. 2018. PMID: 30632919

163

Pathomechanism of 'skin-originated' allergic diseases.

Egawa G. Egawa G. Immunol Med. 2018 Dec;41(4):170-176. doi: 10.1080/25785826.2018.1540257. Epub 2019 Jan 11. Immunol Med. 2018. PMID: 30632910

164

Synergistic induction of interferon-γ by interleukin-2, interleukin-12 and poly(I:C) in a human natural killer cell line.

Majima-Horiuchi H, Komine-Aizawa S, Karasaki-Suzuki M, Izumi Y, Aizawa S, Hayakawa S. Majima-Horiuchi H, et al. Immunol Med. 2018 Sep;41(3):136-141. doi: 10.1080/25785826.2018.1531193. Epub 2018 Nov 17. Immunol Med. 2018. PMID: 30938277

165

The role of nailfold videocapillaroscopy in patients with systemic sclerosis.

Kubo S, Smith V, Cutolo M, Tanaka Y. Kubo S, et al. Immunol Med. 2018 Sep;41(3):113-119. doi: 10.1080/25785826.2018.1531189. Epub 2018 Nov 4. Immunol Med. 2018. PMID: 30938276

166

Clinical significance of myositis-specific autoantibodies.

Nakashima R. Nakashima R. Immunol Med. 2018 Sep;41(3):103-112. doi: 10.1080/25785826.2018.1531188. Epub 2018 Nov 17. Immunol Med. 2018. PMID: 30938275

167

Immunometabolism in rheumatoid arthritis.

Okano T, Saegusa J, Takahashi S, Ueda Y, Morinobu A. Okano T, et al. Immunol Med. 2018 Sep;41(3):89-97. doi: 10.1080/25785826.2018.1531186. Immunol Med. 2018. PMID: 30938274

168

Blood-brain barrier dysfunction in immuno-mediated neurological diseases.

Shimizu F, Nishihara H, Kanda T. Shimizu F, et al. Immunol Med. 2018 Sep;41(3):120-128. doi: 10.1080/25785826.2018.1531190. Epub 2018 Nov 30. Immunol Med. 2018. PMID: 30938273

169

Recent advances in the role of RNA-binding protein, tristetraprolin, in arthritis.

Yamasaki S. Yamasaki S. Immunol Med. 2018 Sep;41(3):98-102. doi: 10.1080/25785826.2018.1531187. Epub 2018 Nov 4. Immunol Med. 2018. PMID: 30938272

170

Successful treatment with tacrolimus of refractory pyoderma gangrenosum with pouchitis after restorative proctocolectomy for ulcerative colitis.

Satake M, Sakuraba H, Hiraga H, Tarakita N, Akemoto Y, Ota S, Hasui K, Nishiya D, Hayamizu S, Kikuchi H, Sawaya M, Chinda D, Mikami T, Shimoyama T, Fukuda S. Satake M, et al. Immunol Med. 2018 Sep;41(3):142-146. doi: 10.1080/25785826.2018.1531194. Epub 2018 Dec 3. Immunol Med. 2018. PMID: 30618342

171

Prediction of therapeutic responses with ultrasonography in RA patients treated with an anti-TNF drug: a retrospective cohort study.

Nozaki Y, Ri J, Sakai K, Shiga T, Inoue A, Nagare Y, Funauchi M, Matsumura I. Nozaki Y, et al. Immunol Med. 2018 Sep;41(3):129-135. doi: 10.1080/25785826.2018.1531192. Epub 2018 Nov 17. Immunol Med. 2018. PMID: 30618341

172

Comparison of fluorescence optical imaging, ultrasonography and clinical examination with magnetic resonance imaging as a reference in active rheumatoid arthritis patients.

Hirano F, Yokoyama-Kokuryo W, Yamazaki H, Tsutsumino M, Sakai R, Satoh S, Kimura T, Tojo N, Kohsaka H, Harigai M. Hirano F, et al. Immunol Med. 2018 Jun;41(2):75-81. doi: 10.1080/13497413.2018.1481578. Epub 2018 Sep 7. Immunol Med. 2018. PMID: 30938268

173

LRG is a novel inflammatory marker clinically useful for the evaluation of disease activity in rheumatoid arthritis and inflammatory bowel disease.

Naka T, Fujimoto M. Naka T, et al. Immunol Med. 2018 Jun;41(2):62-67. doi: 10.1080/13497413.2018.1481582. Epub 2018 Sep 11. Immunol Med. 2018. PMID: 30938267

174

Familial Mediterranean fever: overview of pathogenesis, clinical features and management.

Migita K, Asano T, Sato S, Koga T, Fujita Y, Kawakami A. Migita K, et al. Immunol Med. 2018 Jun;41(2):55-61. doi: 10.1080/13497413.2018.1481579. Epub 2018 Sep 7. Immunol Med. 2018. PMID: 30938266

175

Scrub typhus (Tsutsugamushi disease) in a patient presenting with hemophagocytic syndrome.

Akagi T, Mukai T, Tsuji S, Morita Y. Akagi T, et al. Immunol Med. 2018 Jun;41(2):82-84. doi: 10.1080/13497413.2018.1481581. Epub 2018 Aug 17. Immunol Med. 2018. PMID: 30938265

176

Rocuronium anaphylaxis in a 7-year-old boy during the induction of anesthesia.

Morimoto Y, Satake S, Kamitani A, Yamada M, Saitou M, Torii Y, Shiba R, Hadase C, Yamamoto T. Morimoto Y, et al. Immunol Med. 2018 Jun;41(2):85-88. doi: 10.1080/13497413.2018.1481580. Epub 2018 Jul 30. Immunol Med. 2018. PMID: 30938264

177

Myositis an evolving spectrum of disease.

Barsotti S, Lundberg IE. Barsotti S, et al. Immunol Med. 2018 Jun;41(2):46-54. doi: 10.1080/13497413.2018.1481571. Epub 2018 Sep 11. Immunol Med. 2018. PMID: 30938263

178

Disease modeling of immunological disorders using induced pluripotent stem cells.

Saito MK. Saito MK. Immunol Med. 2018 Jun;41(2):68-74. doi: 10.1080/13497413.2018.1481583. Epub 2018 Sep 7. Immunol Med. 2018. PMID: 30618339

179

Era of steroid sparing in the management of immune-mediated inflammatory diseases.

Kondo T, Amano K. Kondo T, et al. Immunol Med. 2018 Mar;41(1):6-11. doi: 10.1080/09114300.2018.1451593. Epub 2018 Apr 9. Immunol Med. 2018. PMID: 30938261

180

Protein-losing gastroenteropathy in a patient with concomitant systemic lupus erythematosus and Sjögren's syndrome.

Eguchi M, Iwanaga N, Sakai K, Michitsuji T, Tsuji Y, Kawahara C, Kobayashi H, Horai Y, Mori T, Izumi Y, Ito M, Kawakami A. Eguchi M, et al. Immunol Med. 2018 Mar;41(1):34-38. doi: 10.1080/09114300.2018.1451614. Epub 2018 Apr 3. Immunol Med. 2018. PMID: 30938260

181

Successful treatment of tocilizumab-resistant large vessel pulmonary arteritis with infliximab.

Tanimura S, Kato M, Abe N, Ohira H, Tsujino I, Atsumi T. Tanimura S, et al. Immunol Med. 2018 Mar;41(1):39-42. doi: 10.1080/09114300.2018.1451616. Epub 2018 Apr 3. Immunol Med. 2018. PMID: 30938259

182

Interleukin-6 plays a crucial role in the development of subretinal fibrosis in a mouse model.

Sato K, Takeda A, Hasegawa E, Jo YJ, Arima M, Oshima Y, Ryoji Y, Nakazawa T, Yuzawa M, Nakashizuka H, Shimada H, Kimura K, Ishibashi T, Sonoda KH. Sato K, et al. Immunol Med. 2018 Mar;41(1):23-29. doi: 10.1080/09114300.2018.1451609. Epub 2018 Apr 5. Immunol Med. 2018. PMID: 30938258

183

Inhaled steroid inhibits development of total and mite IgE.

Murayama N, Doi S, Inoue T, Takamatsu I, Kameda M, Takeda K, Toyoshima K. Murayama N, et al. Immunol Med. 2018 Mar;41(1):17-22. doi: 10.1080/09114300.2018.1451599. Epub 2018 Apr 3. Immunol Med. 2018. PMID: 30938257

184

Predicting therapeutic response in IgG4-related disease based on cluster analysis.

Yamamoto M, Takano KI, Kamekura R, Suzuki C, Tabeya T, Murakami R, Honda S, Mukai M, Nojima M, Ichimiya S, Himi T, Nakase H, Takahashi H. Yamamoto M, et al. Immunol Med. 2018 Mar;41(1):30-33. doi: 10.1080/09114300.2018.1451613. Epub 2018 Apr 3. Immunol Med. 2018. PMID: 30938256

185

Acute rheumatic fever associated with tenosynovitis and a unique cytokine profile.

Wakiguchi H, Okazaki F, Suzuki Y, Ichimura T, Wakabayashi-Takahara M, Terachi SI, Ouchi K, Hasegawa S. Wakiguchi H, et al. Immunol Med. 2018 Mar;41(1):43-45. doi: 10.1080/09114300.2018.1451617. Epub 2018 Apr 3. Immunol Med. 2018. PMID: 30938255

186

Pediatric rheumatic diseases: a review regarding the improvement of long-term prognosis and the transition to adults.

Mori M. Mori M. Immunol Med. 2018 Mar;41(1):2-5. doi: 10.1080/09114300.2018.1451591. Epub 2018 Apr 3. Immunol Med. 2018. PMID: 30938254

187

New horizons in clinical immunology: applications of induced pluripotent stem cells for the analysis of immune disorders.

Shoda H, Natsumoto B, Fujio K. Shoda H, et al. Immunol Med. 2018 Mar;41(1):12-16. doi: 10.1080/09114300.2018.1451596. Epub 2018 Apr 4. Immunol Med. 2018. PMID: 30938253

188

Publishing Immunological Medicine-changing from Japanese Journal of Clinical Immunology.

Mimori T. Mimori T. Immunol Med. 2018 Mar;41(1):1. doi: 10.1080/09114300.2018.1451588. Epub 2018 Apr 4. Immunol Med. 2018. PMID: 30938252 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

188 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

188 results

Results by year